Metsera Pfizer Novo Nordisk obsesity.

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral and injectable treatments for obesity and diabetes. On Friday, Metsera announced that Pfizer will acquire the company for up to $86.25 per share, including cash and contingent value rights. Metsera’s board said it believes this deal offers the best value and certainty for shareholders. Novo Nordisk, which had increased its offer to $10 billion, announced on Saturday that it would not continue pursuing the acquisition.